Skip to content
Annika Bansal – Lifestyle
Author:
MeiraGTx
MeiraGTx Reports Third Quarter 2026 Financial and Operational Results
November 12, 2026
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
October 27, 2026
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
September 23, 2026
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
August 13, 2026
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 6, 2026
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
July 7, 2026
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
April 16, 2026